Compare WETH & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | ITRM |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 24.3M |
| IPO Year | 2020 | 2018 |
| Metric | WETH | ITRM |
|---|---|---|
| Price | $1.36 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 126.6K | ★ 30.9M |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 57.43 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $45,136,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.78 | $0.03 |
| 52 Week High | $3.68 | $1.16 |
| Indicator | WETH | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 26.10 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.46 | $0.39 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.25 | 3.34 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.